Table 3 Diagnostic performance.

From: PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4–10 ng/ml

Indicator

Cutoff

Sensitivity (95% CI)

Specificity (95% CI)

PPV

NPV

AUC (95% CI)

P for AUC

Training cohort

 PSAD

0.162

73.3% (63.0–82.4%)

62.1% (55.8–68.5%)

41.8% (33.9–50.1%)

86.5% (80.4–91.2%)

0.712 (0.648–0.775)

P < 0.001a

 PI-RADS

 ≥ 3

95.4% (88.8–98.2%)

55.9% (49.6–62.1%)

44.4% (37.1–51.8%)

97.1% (92.6–99.2%)

0.875 (0.834–0.916)

0.01a

 ≥ 4

86.2% (77.4–91.9%)

84.7% (79.6–88.8%)

67.6% (58.0–76.1%)

94.3% (90.3–97.0%)

 PSAD + PI-RADS

–

84.7% (75.8–91.8%)

87.4% (82.4–91.3%)

71.2% (61.4–79.6%)

94.1% (90.1–96.8%)

0.893 (0.853–0.933)

–

Validation cohort

 PSAD

0.183

50.0% (31.9–68.1%)

75.5% (65.8–83.6%)

40% (24.9–56.7%)

82.2% (72.7–89.5%)

0.677 (0.569–0.785)

P < 0.001a

 PI-RADS

 ≥ 3

96.9% (84.3–994%)

56.1% (46.3–65.5%)

41.9% (30.5–53.9%)

98.2% (90.4–100%)

0.829 (0.759–0.899)

0.02a

 ≥ 4

71.9% (54.6–84.4%)

81.6% (72.9–88.1%)

56.1% (39.7–71.5%)

89.9% (81.7–95.3%)

 PSAD + PI-RADS

–

83.7% (62.7–94.7%)

84.4% (76.0–91.2%)

64.3% (48.0–78.4%)

94.3% (87.2–98.1%)

0.871 (0.807–0.934)

–

  1. AUC area under the receiver operating characteristic curve, CI confidence interval, NPV negative predictive value, REF reference, PI-RADS prostate imaging reporting and data system, PPV positive predictive value, PSAD prostate-specific antigen density.
  2. aCompared with PSAD + PI-RADS.
Back to article page